---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342397"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2026-08-10T20:11:49+00:00"
generated_at: "2026-08-10T20:13:16.719493+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProKidney Q2 2026 loss $46.4M, cash $181.6M; PROACT 1 interim enrollment complete

## Summary
- Completed enrollment for PROACT 1 accelerated approval analysis (~320 pts); topline eGFR slope results expected Q2 2027.
- Full enrollment of ~470 patients on track for H2 2026; confirmatory results anticipated H2 2029.
- Appointed Kenneth Locke as CTO in June 2026; 25+ years R&D/CMC/supply chain experience.
- Cash and equivalents $181.6M at June 30, 2026, down from $224.9M at March 31, 2026; supports ops into mid-2027.
- Net loss before noncontrolling interest $46.4M in Q2 2026 vs $37.0M in Q2 2025; R&D expenses rose to $36.1M.

## SEC filing metadata
- accession: 0001193125-26-342397
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2026-08-10T20:11:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/0001193125-26-342397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/prok-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342397
- JSON: https://secwatch.observer/filing/0001193125-26-342397.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.